Article
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Cancer discovery - 1 Mar 2017
Goyal Lipika, Saha Supriya K, Liu Leah Y, Siravegna Giulia, Leshchiner Ignaty, Ahronian Leanne G, Lennerz Jochen K, Vu Phuong, Deshpande Vikram, Kambadakone Avinash, Mussolin Benedetta, Reyes Stephanie, Henderson Laura, Sun Jiaoyuan Elisabeth, Van Seventer Emily E, Gurski Joseph M, Baltschukat Sabrina, Schacher-Engstler Barbara, Barys Louise, Stamm Christelle, Furet Pascal, Ryan David P, Stone James R, Iafrate A John, Getz Gad, Porta Diana Graus, Tiedt Ralph, Bardelli Alberto, Juric Dejan, Corcoran Ryan B, Bardeesy Nabeel, Zhu Andrew X
Abstract excerpt
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with FGFR2 fusion-positive ICC in a phase II trial, but the durability of response was limited in some patients. Here, we report the molecular basis for acquired...
Topics
Join the communities discussing this publication.